Type 1 diabetes affects 17 million people globally and there is no cure; instead, patients must inject themselves with insulin daily and continually check their blood sugar levels to control their condition.
The goal of the INNODIA project is to advance our understanding of type 1 diabetes and address the lack of tools and technologies that will allow clinicians to predict, evaluate and prevent the onset and progression of type 1 diabetes. For patients, this would mean the ability to predict the rate at which their disease will progress. The project has set up a patient advisory committee (PAC) to ensure the work is in line with patients’ needs.
The knowledge and tools generated by the project have helped researchers in INNODIA and its sister project INNODIA HARVEST to optimise the design of four clinical trials of treatments for preventing and curing this debilitating disease. In 2020, trials started in children, adolescents and adults, who have been diagnosed with type one diabetes within the past 6 weeks and are aged from 5 to 45 years. All trials are running on the INNODIA Master Protocol, and the PAC is helping with recruitment for the trials.